PMID- 21437624
OWN - NLM
STAT- MEDLINE
DCOM- 20111018
LR  - 20211020
IS  - 1573-4919 (Electronic)
IS  - 0300-8177 (Linking)
VI  - 353
IP  - 1-2
DP  - 2011 Jul
TI  - Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
PG  - 251-7
LID - 10.1007/s11010-011-0793-6 [doi]
AB  - Altered levels of matrix metalloproteinases (MMPs) may reflect relevant 
      pathogenetic mechanisms of disease conditions. The objective of this study was to 
      compare the plasma levels of MMPs and tissue inhibitors of MMPs (TIMPs) in 
      polycystic ovary syndrome (PCOS) patients with those found in healthy ovulatory 
      controls and to examine whether the levels of these biomarkers are associated 
      with clinical and biochemical features of this syndrome. Sixty-five healthy 
      ovulatory subjects (controls) and 80 patients with PCOS were include in this 
      study. MMP-2, MMP-8, MMP-9, TIMP-1, TIMP-2 concentrations were measured in plasma 
      samples by gelatin zymography or enzyme-linked immunoassays. MMP-2, MMP-8, MMP-9, 
      and TIMP-1 levels were similar in PCOS patients and in healthy controls (P > 
      0.05). PCOS patients had lower plasma TIMP-2 levels than healthy controls (P < 
      0.05). We found higher MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in PCOS patients than 
      in healthy controls (all P < 0.05). Testosterone levels correlated positively 
      with the MMP-9/TIMP-1 ratio and negatively with TIMP-2 levels (r = 0.26, P < 0.01 
      and r = -0.21, P = 0.02, respectively). In addition, only testosterone was an 
      independent predictor of TIMP-2 levels (estimate = -0.35, P = 0.04) and the 
      MMP-9/TIMP-1 ratio (estimate = 0.01, P = 0.04). We found evidence indicating that 
      the balance between MMPs and TIMPs in women with PCOS is altered, probably due to 
      androgen excess found in these women.
FAU - Gomes, Valeria A
AU  - Gomes VA
AD  - Department of Pharmacology, Faculty of Medical Sciences, State University of 
      Campinas, Campinas, SP 13081-970, Brazil.
FAU - Vieira, Carolina S
AU  - Vieira CS
FAU - Jacob-Ferreira, Anna L
AU  - Jacob-Ferreira AL
FAU - Belo, Vanessa A
AU  - Belo VA
FAU - Soares, Gustavo M
AU  - Soares GM
FAU - Fernandes, Janaina B F
AU  - Fernandes JB
FAU - Ferriani, Rui A
AU  - Ferriani RA
FAU - Tanus-Santos, Jose E
AU  - Tanus-Santos JE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110325
PL  - Netherlands
TA  - Mol Cell Biochem
JT  - Molecular and cellular biochemistry
JID - 0364456
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 0 (Tissue Inhibitor of Metalloproteinases)
RN  - 127497-59-0 (Tissue Inhibitor of Metalloproteinase-2)
RN  - 3XMK78S47O (Testosterone)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.34 (Matrix Metalloproteinase 8)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Analysis of Variance
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Matrix Metalloproteinase 2/blood
MH  - Matrix Metalloproteinase 8/blood
MH  - Matrix Metalloproteinase 9/blood
MH  - Matrix Metalloproteinases/*blood
MH  - Polycystic Ovary Syndrome/*blood
MH  - Testosterone/blood
MH  - Tissue Inhibitor of Metalloproteinase-1/blood
MH  - Tissue Inhibitor of Metalloproteinase-2/blood
MH  - Tissue Inhibitor of Metalloproteinases/*blood
MH  - Young Adult
EDAT- 2011/03/26 06:00
MHDA- 2011/10/19 06:00
CRDT- 2011/03/26 06:00
PHST- 2010/12/15 00:00 [received]
PHST- 2011/03/17 00:00 [accepted]
PHST- 2011/03/26 06:00 [entrez]
PHST- 2011/03/26 06:00 [pubmed]
PHST- 2011/10/19 06:00 [medline]
AID - 10.1007/s11010-011-0793-6 [doi]
PST - ppublish
SO  - Mol Cell Biochem. 2011 Jul;353(1-2):251-7. doi: 10.1007/s11010-011-0793-6. Epub 
      2011 Mar 25.